These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 27491559)

  • 1. Neo-tanshinlactone selectively inhibits the proliferation of estrogen receptor positive breast cancer cells through transcriptional down-regulation of estrogen receptor alpha.
    Lin W; Huang J; Liao X; Yuan Z; Feng S; Xie Y; Ma W
    Pharmacol Res; 2016 Sep; 111():849-858. PubMed ID: 27491559
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antitumor Agents. 239. Isolation, structure elucidation, total synthesis, and anti-breast cancer activity of neo-tanshinlactone from Salvia miltiorrhiza.
    Wang X; Bastow KF; Sun CM; Lin YL; Yu HJ; Don MJ; Wu TS; Nakamura S; Lee KH
    J Med Chem; 2004 Nov; 47(23):5816-9. PubMed ID: 15509181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sesterterpene MHO7 suppresses breast cancer cells as a novel estrogen receptor degrader.
    Zhao Y; Zhao C; Lu J; Wu J; Li C; Hu Z; Tian W; Yang L; Xiang J; Zhou H; Deng Z; Huang J; Hong K
    Pharmacol Res; 2019 Aug; 146():104294. PubMed ID: 31175940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the potential activity of major dietary compounds as selective estrogen receptor modulators in two distinct cell models for proliferation and differentiation.
    Lecomte S; Lelong M; Bourgine G; Efstathiou T; Saligaut C; Pakdel F
    Toxicol Appl Pharmacol; 2017 Jun; 325():61-70. PubMed ID: 28396216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wilms' tumor 1 suppressor gene mediates antiestrogen resistance via down-regulation of estrogen receptor-alpha expression in breast cancer cells.
    Han Y; Yang L; Suarez-Saiz F; San-Marina S; Cui J; Minden MD
    Mol Cancer Res; 2008 Aug; 6(8):1347-55. PubMed ID: 18708366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
    Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
    Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Keratinocyte growth factor (KGF) regulates estrogen receptor-alpha (ER-alpha) expression and cell apoptosis via phosphatidylinositol 3-kinase (PI3K)/Akt pathway in human breast cancer cells.
    Chang HL; Sugimoto Y; Liu S; Wang LS; Huang YW; Ye W; Lin YC
    Anticancer Res; 2009 Aug; 29(8):3195-205. PubMed ID: 19661335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signal transducer and activator of transcription 5b, c-Src, and epidermal growth factor receptor signaling play integral roles in estrogen-stimulated proliferation of estrogen receptor-positive breast cancer cells.
    Fox EM; Bernaciak TM; Wen J; Weaver AM; Shupnik MA; Silva CM
    Mol Endocrinol; 2008 Aug; 22(8):1781-96. PubMed ID: 18550772
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells.
    Chang HL; Sugimoto Y; Liu S; Ye W; Wang LS; Huang YW; Lin YC
    Anticancer Res; 2006; 26(3A):1773-84. PubMed ID: 16827106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines.
    Pink JJ; Jordan VC
    Cancer Res; 1996 May; 56(10):2321-30. PubMed ID: 8625307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
    Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
    J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
    Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
    Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
    J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multimodal Assessment of Estrogen Receptor mRNA Profiles to Quantify Estrogen Pathway Activity in Breast Tumors.
    Muthukaruppan A; Lasham A; Woad KJ; Black MA; Blenkiron C; Miller LD; Harris G; McCarthy N; Findlay MP; Shelling AN; Print CG
    Clin Breast Cancer; 2017 Apr; 17(2):139-153. PubMed ID: 27756582
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ESR1 mutations affect anti-proliferative responses to tamoxifen through enhanced cross-talk with IGF signaling.
    Gelsomino L; Gu G; Rechoum Y; Beyer AR; Pejerrey SM; Tsimelzon A; Wang T; Huffman K; Ludlow A; Andò S; Fuqua SAW
    Breast Cancer Res Treat; 2016 Jun; 157(2):253-265. PubMed ID: 27178332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of the new SERM arzoxifene on growth and gene expression in MCF-7 breast cancer cells.
    Freddie CT; Larsen SS; Bartholomaeussen M; Lykkesfeldt AE
    Mol Cell Endocrinol; 2004 Apr; 219(1-2):27-36. PubMed ID: 15149724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of estrogen receptor expression in breast cancer.
    Martin MB; Saceda M; Lindsey RK
    Adv Exp Med Biol; 1993; 330():143-53. PubMed ID: 8368130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased BRCA1 confers tamoxifen resistance in breast cancer cells by altering estrogen receptor-coregulator interactions.
    Wen J; Li R; Lu Y; Shupnik MA
    Oncogene; 2009 Jan; 28(4):575-86. PubMed ID: 18997820
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anacardic acid inhibits estrogen receptor alpha-DNA binding and reduces target gene transcription and breast cancer cell proliferation.
    Schultz DJ; Wickramasinghe NS; Ivanova MM; Isaacs SM; Dougherty SM; Imbert-Fernandez Y; Cunningham AR; Chen C; Klinge CM
    Mol Cancer Ther; 2010 Mar; 9(3):594-605. PubMed ID: 20197399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.